2024
Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry
Lebwohl M, Strober B, Schrader A, Li A, Eckmann T, Zhu B, Malatestinic W, Birt J, Feely M, Blauvelt A. Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry. Drugs - Real World Outcomes 2024, 11: 451-464. PMID: 38914857, PMCID: PMC11365873, DOI: 10.1007/s40801-024-00439-w.Peer-Reviewed Original ResearchTumor necrosis factor inhibitorsInvestigator's Global AssessmentEffectiveness of ixekizumabDermatology Life Quality IndexDermatology Life Quality Index 0/1Body surface areaIL-23iCorEvitas Psoriasis RegistryIL-12/23iPatient-reported outcomesIL-17iPsoriasis RegistryBiologic therapySkin painSwitching to ixekizumabIL-23 inhibitorsDisease severityInterleukin-23 inhibitorAdjusted mean changesMultivariable modified Poisson regressionInterleukin-12/23 inhibitorsFollow-up visitConfidence intervalsModified Poisson regressionReal-world study
2023
Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry
Strober B, Duffin K, Lebwohl M, Sima A, Janak J, Patel M, Photowala H, Garg V, Bagel J. Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry. Journal Of Dermatological Treatment 2023, 35: 2287401. PMID: 38073528, DOI: 10.1080/09546634.2023.2287401.Peer-Reviewed Original ResearchConceptsDermatology Life Quality IndexPatient-reported outcomesArea involvementActivity impairmentDisease severityPsoriasis RegistryPatients' HRQOLPsoriasis symptomsSymptom severityImproved disease severityPsoriasis disease severityBaseline disease severityImpact of psoriasisHealth-related qualityWork abilityPatients' physical functioningLife Quality IndexImpaired work abilitySevere psoriasisSystemic treatmentWorse outcomesPhysical functioningHRQoLAdequate treatmentGreater HRQOL
2022
Sex Differences in Moderate to Severe Psoriasis: Analysis of the Psoriasis Longitudinal Assessment and Registry
Goldburg S, Chen R, Langholff W, Lafferty K, Gooderham M, de Jong E, Strober B. Sex Differences in Moderate to Severe Psoriasis: Analysis of the Psoriasis Longitudinal Assessment and Registry. Journal Of Psoriasis And Psoriatic Arthritis 2022, 7: 132-139. PMID: 39296535, PMCID: PMC11361528, DOI: 10.1177/24755303221099848.Peer-Reviewed Original ResearchPsoriasis Longitudinal AssessmentDisease characteristicsDermatology Life Quality Index scoresDisease severitySystemic therapy-naïve patientsLife Quality Index scoresLongitudinal assessmentPhysician global assessmentSystemic steroid therapyLifestyle risk factorsTherapy-naïve patientsNonmelanoma skin cancerObjective disease severityBody surface areaHistory of anxietyQuality Index scoresQuality of lifeChi-square testPsoriasis characteristicsSteroid therapySevere psoriasisTherapy-naïveDisease durationBiologic-naïvePatient characteristics
2021
27876 The PASI-HD improved precision in measuring disease severity in subjects with mild to moderate plaque psoriasis treated with roflumilast cream, a phosphodiesterase-4 inhibitor
Papp K, Lebwohl M, Kircik L, Pariser D, Strober B, Krueger G, Berk D, Navale L, Higham R. 27876 The PASI-HD improved precision in measuring disease severity in subjects with mild to moderate plaque psoriasis treated with roflumilast cream, a phosphodiesterase-4 inhibitor. Journal Of The American Academy Of Dermatology 2021, 85: ab164. DOI: 10.1016/j.jaad.2021.06.670.Peer-Reviewed Original ResearchThe Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score
Papp K, Lebwohl M, Kircik L, Pariser D, Strober B, Krueger G, Berk D, Navale L, Higham R. The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score. Dermatology And Therapy 2021, 11: 1079-1083. PMID: 34236691, PMCID: PMC8322185, DOI: 10.1007/s13555-021-00572-2.Peer-Reviewed Original Research
2020
PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis
Gold L, Hansen J, Patel D, Veverka K, Strober B. PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis. Journal Of The American Academy Of Dermatology 2020, 83: 131-138. PMID: 32430142, DOI: 10.1016/j.jaad.2020.02.077.Peer-Reviewed Original ResearchConceptsCal/BD foamSevere psoriasisWeek 4Disease severityPhysician global assessmentProportion of patientsBody surface areaSpearman correlationTherapeutic response measuresCalcipotriol/Dipropionate foamMild psoriasisPlaque psoriasisPsoriasis AreaBland-Altman plotsPsoriasis severityTherapeutic responseMean improvementWeek 1PsoriasisGlobal assessmentSeverity IndexInterrater reliabilitySeverityPASI
2019
US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry
Strober B, Germino R, Guana A, Greenberg J, Litman H, Guo N, Lebwohl M. US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry. Journal Of Dermatological Treatment 2019, 31: 333-341. PMID: 31035822, DOI: 10.1080/09546634.2019.1603361.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesCorrona Psoriasis RegistryGlobal assessment scoreBody surface areaReal-world effectivenessPsoriasis RegistryReal-world studySecukinumab treatmentDisease severityInvestigator's Global Assessment scoreMajority of patientsTreatment of psoriasisQuality of lifeEligible patientsSecukinumabPatientsSignificant improvementFollowAssessment scoresRegistryVisitsWork productivityPsoriasisDaily activitiesTreatment
2018
Methotrexate treatment of generalized granuloma annulare: a retrospective case series
Naka F, Strober B. Methotrexate treatment of generalized granuloma annulare: a retrospective case series. Journal Of Dermatological Treatment 2018, 29: 720-724. PMID: 29488435, DOI: 10.1080/09546634.2018.1447075.Peer-Reviewed Original ResearchConceptsGeneralized granuloma annulareRetrospective case seriesCase seriesMethotrexate treatmentGranuloma annulareAdverse effectsFirst-line therapyEfficacy of methotrexateMajority of patientsAvailable therapeutic modalitiesSmall case seriesIndividual case reportsLow internal validityDisease improvementInitial doseTreatment optionsCase reportComplete clearancePartial clearanceHair lossTherapeutic modalitiesPatientsSkin diseasesControl groupDisease severity
2017
Greater Efficacy with Secukinumab Treatment is Associated with Greater Psoriasis Symptom Relief: Results from Secukinumab Clinical Trial Data
Gottlieb A, Strober B, Lebwohl M, Kaufmann R, Pariser D, Narbutas R, Nyirady J, Zhao Y, Herrera V, McLeod L, Odom D, Elewski B. Greater Efficacy with Secukinumab Treatment is Associated with Greater Psoriasis Symptom Relief: Results from Secukinumab Clinical Trial Data. Journal Of Psoriasis And Psoriatic Arthritis 2017, 2: 73-80. DOI: 10.1177/247553031700200206.Peer-Reviewed Original ResearchPsoriasis-related itchingWeek 12Disease severityBenefits of secukinumabInterleukin-17A antagonistSevere plaque psoriasisPatient-reported symptomsClinical trial dataDisease severity scoreQuality of lifeTraditional clinical measuresBackground PsoriasisPASI responseSecukinumab treatmentPlaque psoriasisComplete reliefSymptom reliefSeverity scoreClinical dataResponder statusClinical measuresGreater efficacyTrial dataSecukinumabTreatment effects
2007
National Psoriasis Foundation Clinical Consensus on Disease Severity
Pariser DM, Bagel J, Gelfand JM, Korman NJ, Ritchlin CT, Strober BE, Van Voorhees AS, Young M, Rittenberg S, Lebwohl MG, Horn EJ. National Psoriasis Foundation Clinical Consensus on Disease Severity. JAMA Dermatology 2007, 143: 239-242. PMID: 17310004, DOI: 10.1001/archderm.143.2.239.Peer-Reviewed Original ResearchConceptsNational Psoriasis Foundation Medical BoardConsensus statementSeverity criteriaClinical practiceClinical consensus statementTask ForceCategory of patientsNational Psoriasis FoundationCurrent clinical practiceMedical boardsPlaque psoriasisSevere psoriasisAppropriate therapyPsoriasis therapyClinical consensusInsurance payerDisease severityPsoriasisPatientsCurrent standardTherapyMedical professionalsSeverityExpert opinionMD